Payment overview · 2025
General Payments
$206.53
6 reported records · 3 companies
Healthcare provider profile · identity verified
Arthur L Sheppell, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · DENVILLE, NJ · NPI 1871698274
Verified facts
What the public records show
CMS Open Payments records show Arthur L Sheppell, MD received $206.53 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 83.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $172.56 | 83.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.44 | 8.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.53 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.53 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 112 |
| Eliquis | Apixaban | 434 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 81 |
| Losartan Potassium | Losartan Potassium | 235 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 40 |
| Gabapentin | Gabapentin | 195 | 49 |
| Donepezil Hcl | Donepezil Hcl | 187 | 35 |
| Sertraline Hcl | Sertraline Hcl | 182 | 43 |
| Lisinopril | Lisinopril | 181 | 58 |
| Alprazolam | Alprazolam | 165 | 53 |
| Mirtazapine | Mirtazapine | 161 | 37 |
| Furosemide | Furosemide | 159 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 44 |
| Memantine Hcl | Memantine Hcl | 137 | 19 |
| Divalproex Sodium | Divalproex Sodium | 133 | 29 |
| Metformin Hcl | Metformin Hcl | 126 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 39 |
| Simvastatin | Simvastatin | 115 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 32 |
| Potassium Chloride | Potassium Chloride | 110 | 30 |
| Xarelto | Rivaroxaban | 107 | 16 |
| Torsemide | Torsemide | 106 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 32 |
| Omeprazole | Omeprazole | 95 | 24 |
| Spironolactone | Spironolactone | 92 | 22 |
| Finasteride | Finasteride | 90 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 16 |
| Allopurinol | Allopurinol | 86 | 19 |
| Famotidine | Famotidine | 79 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 19 |
| Carvedilol | Carvedilol | 68 | 16 |
| Tradjenta | Linagliptin | 65 | suppressed |
| Levetiracetam | Levetiracetam | 59 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 33 |
| Baclofen | Baclofen | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 15 |
| Trazodone Hcl | Trazodone Hcl | 54 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 19 |
| Prednisone | Prednisone | 48 | 25 |
| Midodrine Hcl | Midodrine Hcl | 45 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 43 | 15 |
| Latanoprost | Latanoprost | 43 | 15 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 29 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 25 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Nystatin | Nystatin | 37 | 19 |
| Lorazepam | Lorazepam | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Valsartan | Valsartan | 25 | 14 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Milrinone In 5% Dextrose | Milrinone Lactate/D5w | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 12 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.53 · 6 records | Lilly USA, LLC | JYNARQUE, KISUNLA, NUPLAZID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error